（来源：嘉兴日报） 自2018年版基药目录实施以来，已有8年未变。其间，集采已开展多批，医保目录也每年动态调整，而 基药目录静止不动，导致许多基层医院的药品配备更新滞后。集采中选的质优价廉药品若未在基药目录 内，基层医院受制于"基药配备品种金额占比"等考核，往往难以或不愿大量采购配备。结果便是，集采 省下的钱、医保扩大的保障网，在抵达基层患者时出现了令人遗憾的"断点"。 基药目录只有顺势调整，才能赶上惠民的快车。新《办法》将基药目录调整周期明确为"原则上不超过3 年"，正是为了扭转这种滞后局面。唯有让基药目录及时吸纳经过集采验证的药品，将临床必需且医保 覆盖的新药好药纳入其中，才能让惠民政策形成合力，畅通无阻地抵达基层。 此次新《办法》的出台，为基药目录"新陈代谢"建立了更科学、更规范的机制。目录调整只是起点，其 与集采、医保支付等政策的深度衔接能否在操作层面无缝落地，能否切实打破基层用药壁垒，仍需拿出 更精细的配套方案和更大的执行力度。只有当基药目录赶上惠民政策的快车，广大患者方能及时在家门 口获得药价大降和新药增加等红利。 春节前，国家卫生健康委等11部门联合印发新的《国家基本药物目录管理办法》，其中特别 ...

此次三款药物纳入医保，不仅降低了以往高昂的治疗成本，更通过医保报销机制切实缓解患者的经济压 力，让这份"生命希望"真正变得触手可及。针对临床未满足的需求和治疗费用的降低，科伦博泰总经理 兼首席执行官葛均友博士表示，"当你知道自己的创新研究成果可能改变一个疾病领域的治疗格局，能 够填补目前治疗不了的领域时，那种使命感超越了任何商业考量。虽然医保目录内已有同类治疗产品， 但我们愿意以更加亲民的价格推进国产替代，防止患者因病致贫、因病返贫。" 智通财经APP了解到，1月1日，《国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创 新药品目录(2025年)》正式落地实施。在这份新目录中，科伦博泰生物-B(06990)自主研发的芦康沙妥珠 单抗(佳泰莱)、西妥昔单抗N01(达泰莱)与塔戈利单抗(科泰莱)三款创新药物成功跻身其中。 据悉，对于晚期三阴性乳腺癌患者及EGFR-TKI治疗失败的非小细胞肺癌患者而言，传统治疗手段往往 收效甚微。而作为科伦博泰自主研发的国内首个获完全批准上市的国产ADC(抗体药物偶联物)，芦康沙 妥珠单抗于2024年11月正式获批，用于治疗既往至少接受过2种系统治疗(其中至少1种针对晚期 ...

中关村（000931）(000931.SZ)公告，公司全资子公司北京中关村四环医药开发有限责任公司(四环医药) 之控股子公司北京华素制药股份有限公司(北京华素)及其全资子公司山东华素制药有限公司(山东华 素)、四环医药之控股子公司多多药业有限公司(多多药业)所属部分药品入选《国家基本医疗保险、生育 保险和工伤保险药品目录(2025年)》，公司共计34个在产产品入选《医保目录2025年》。 ...

Group 1 - The company and its subsidiaries have a total of 218 products included in the new National Medical Insurance Drug List, with 94 classified as Category A and 124 as Category B [1] - Notable products include injectable Aripiprazole microspheres, which were included through negotiation, and injectable Triptorelin microspheres, which have a new indication [1] - The inclusion of these products is expected to enhance market expansion and improve drug accessibility, positively impacting the company's future operating performance [1] Group 2 - The new Medical Insurance Drug List will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The company has received clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating primary hyperaldosteronism [1][2] - SAL0140 is a proprietary aldosterone synthase inhibitor, with potential indications including uncontrolled hypertension, primary hyperaldosteronism, and chronic kidney disease (CKD) [1] - The drug is expected to lower aldosterone levels in patients, potentially reducing blood pressure and organ damage, indicating significant development potential [1] Group 2 - The company’s drugs Xinchaotuo and Fulitan have been newly included in the National Medical Insurance Directory, while Ennaero has successfully renewed its inclusion [3][4] - Xinchaotuo is the first approved ARNI co-crystal drug in China, showing significant blood pressure reduction in clinical trials, with a notable average decrease of 25.07 mmHg to 28.22 mmHg after 12 weeks of treatment [7] - Fulitan is a compound formulation that effectively lowers blood pressure while minimizing adverse effects, making it suitable for salt-sensitive and elderly hypertensive patients [7][9] Group 3 - Ennaero is a new generation HIF-PHI drug approved for treating anemia in CKD patients, demonstrating high efficacy and safety [11][12] - The company has established an innovative product matrix in the cardiovascular chronic disease field, focusing on the heart-kidney metabolic syndrome [14] - The new medical insurance directory will be effective from January 1, 2026, and the company aims to enhance drug accessibility and meet unmet clinical needs [14]

Core Viewpoint - The release of the 2025 version of the basic medical insurance directory and the first commercial insurance directory is expected to support innovation in the CXO industry, leading to a potential performance recovery in the second half of the year [1] Summary by Categories Industry Outlook - The report indicates that several companies' core innovative products have been included in the medical insurance directory [1] - Despite ongoing pressures on medical insurance revenue due to macroeconomic conditions and aging populations, attention is drawn to the renewal of national centralized procurement [1] Commercial Insurance - The initial commercial insurance directory is expected to have limited short-term impact on product sales due to the small scale of commercial insurance [1] - However, the significance of the commercial insurance directory is highlighted as it may pave the way for the expansion of commercial medical insurance in China, marking the beginning of a diversified payment system development [1] Company Recommendations - The report recommends buying shares in the following companies: - Sanofi (01530) - Genscript Biotech (02273) - WuXi AppTec (02268) - Genor Biopharma (02367) - Innovent Biologics (01801) - China Biologic Products (01177) [1]

Summary of Conference Call on Commercial Health Insurance and Innovative Drugs Industry Overview - The conference focused on the commercial health insurance (CHI) sector in China, particularly its integration with the national medical insurance system and the implications for innovative drug companies [1][2]. Key Points and Arguments Integration of Commercial Health Insurance and National Medical Insurance - The National Healthcare Security Administration (NHSA) has led the establishment of a commercial insurance directory, addressing fragmentation in the commercial insurance industry and enhancing the importance of pharmaceutical companies and their products [1][3]. - The commercial health insurance directory aims to provide a platform for innovative drugs, similar to centralized procurement but with a greater emphasis on clinical and economic evaluations rather than just fund calculations [2][4]. Innovative Drug Coverage and Payment Models - Commercial health insurance is adapting to high treatment costs, such as CAR-T therapy, by implementing partial reimbursement and pay-for-performance models to alleviate patient financial burdens [1][5]. - The NHSA's increasing payment for innovative drugs is projected to reach approximately CNY 200 billion by 2024, yet the share of commercial insurance remains low, around CNY 12.5 billion [7][10]. Market Dynamics and Challenges - The high-end medical insurance market in China is currently underdeveloped, with a total market size of less than CNY 10 billion, primarily due to economic factors and the limited purchasing power of potential customers [8][9]. - The commercial health insurance sector is expected to see significant growth, with projections indicating that by 2030, health insurance investments could reach CNY 25 trillion, with CNY 500 billion allocated for innovative drugs, increasing the reimbursement share from 1/16 to 1/4 [10][11]. Future Trends and Opportunities - The future growth of commercial health insurance is anticipated to focus on mid-tier medical insurance, particularly for patients with pre-existing conditions, which can fill gaps in the current healthcare system [13][19]. - The integration of commercial insurance with national healthcare is expected to facilitate a one-stop settlement model, enhancing patient access to innovative treatments and improving overall healthcare service quality [11][27]. Characteristics of Newly Added Drugs - The drugs included in the commercial insurance directory this year are characterized by small market sizes, high costs, and uncertain efficacy, which allows for real-world studies to support future inclusion in the national insurance system [20][21]. Operational Changes in Insurance Companies - Future operational changes in commercial insurance companies may include direct settlement models, where patients do not need to pay upfront, and a focus on different customer segments through business separation [25][27]. Additional Important Insights - The average reimbursement rate for million medical insurance is around 40%, indicating a significant portion of funds is allocated to operational costs rather than patient payouts [18]. - The commercial health insurance market in China has substantial growth potential, with current insurance density and depth significantly lower than OECD averages, suggesting room for expansion [16][17]. This summary encapsulates the critical insights from the conference call, highlighting the evolving landscape of commercial health insurance in China and its implications for innovative drug companies.

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that certain self-owned or imported products from its wholly-owned or controlled subsidiaries have been included in the National Medical Insurance Catalog for 2025, which is expected to facilitate market expansion and increase product sales, although it will not have a significant impact on the company's performance in the short term [1] Group 1 - The innovative drug Aibegesitin α injection (Yilishu), imported general agent product Dihyaluronic Acid Sodium Injection (Yinikon), and Compound Huangdai Tablets (Baixuekang) are included in the catalog [1] - The inclusion of these products in the medical insurance catalog is beneficial for market development and sales growth [1] - The impact on the company's performance will be limited in the short term [1]

Core Viewpoint - Kolun Pharmaceutical (002422.SZ) announced that five of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) as per the notification from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The inclusion of five products in the National Basic Medical Insurance Drug Catalog is a significant development for the company [1] - This move is expected to enhance the market access and sales potential of the included products [1] - The announcement reflects the company's alignment with national healthcare policies and its commitment to expanding its product offerings in the healthcare sector [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has successfully negotiated to include its proprietary product, Yao Xue Qu Feng Zhi Tong Granules, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to positively impact the product's market promotion and sales scale [1] Group 1 - The product Yao Xue Qu Feng Zhi Tong Granules is an innovative traditional Chinese medicine developed by the company [1] - This is the first time the product has been included in the 2025 Medical Insurance Catalog, which will facilitate its market access and hospital entry [1] - The inclusion is anticipated to have a positive effect on the company's future operating performance and market share, although it will not significantly impact short-term financial results [1]